Loading...
XSTO
IDLDX
Market cap13mUSD
May 26, Last price  
0.57SEK
1D
2.50%
1Q
-1.88%
Jan 2017
-91.80%
IPO
-84.71%
Name

AroCell AB (publ)

Chart & Performance

D1W1MN
P/E
P/S
2.30
EPS
Div Yield, %
Shrs. gr., 5y
41.80%
Rev. gr., 5y
164.62%
Revenues
57m
+33.45%
26,8540000460,21754,606502,033781,841442,69784,00011,996,00036,986,00043,039,00057,436,000
Net income
-42m
L-28.41%
-2,152,234-3,584,151-3,156,941-3,732,929-6,368,852-7,478,995-9,234,943-17,270,758-20,757,029-16,201,966-19,459,000-50,026,000-58,973,000-59,297,000-42,449,000
CFO
-2m
L-82.45%
-2,593,000000-9,127,552-7,167,532-15,235,183-16,407,394-15,055,220-18,902,000-28,206,000-13,694,000-13,436,000-2,358,000

Profile

AroCell AB (publ), a vitro diagnostics company, focuses on monitoring of hematological malignancies, breast cancer, and other solid tumors. The company develops, manufactures, and sells AroCell TK 210 ELISA, an immunoassay kit for the determination of Thymidine Kinase 1 in human blood. It also offers TUBEX TF, a bacteriological rapid test for diagnosis of typhoid fever. The company was formerly known as Xi Bao Research AB and changed its name to AroCell AB (publ) in 2006. AroCell AB (publ) was incorporated in 2000 and is based in Uppsala, Sweden.
IPO date
May 25, 2011
Employees
26
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
57,436
33.45%
43,039
16.37%
36,986
208.32%
Cost of revenue
92,414
103,453
99,339
Unusual Expense (Income)
NOPBT
(34,978)
(60,414)
(62,353)
NOPBT Margin
Operating Taxes
(326)
Tax Rate
NOPAT
(34,978)
(60,414)
(62,027)
Net income
(42,449)
-28.41%
(59,297)
0.55%
(58,973)
17.88%
Dividends
Dividend yield
Proceeds from repurchase of equity
250
81,811
BB yield
-0.25%
-61.27%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
(1,000)
6,124
Net debt
(47,785)
(50,723)
(65,189)
Cash flow
Cash from operating activities
(2,358)
(13,436)
(13,694)
CAPEX
(1,279)
(4,058)
Cash from investing activities
(581)
(1,280)
(10,117)
Cash from financing activities
250
70,598
FCF
(37,288)
(58,132)
(65,763)
Balance
Cash
47,785
50,723
65,189
Long term investments
Excess cash
44,913
48,571
63,340
Stockholders' equity
(319,810)
(277,361)
(218,064)
Invested Capital
441,007
441,007
440,758
ROIC
ROCE
EV
Common stock shares outstanding
230,361
230,361
215,354
Price
0.39
-10.76%
0.44
-29.52%
0.62
-34.74%
Market cap
89,841
-10.76%
100,668
-24.60%
133,519
46.17%
EV
42,056
49,945
68,330
EBITDA
(34,978)
(14,877)
(15,171)
EV/EBITDA
Interest
13
5
Interest/NOPBT